Product

Atripla

1 clinical trial

1 indication

Indication

HIV-1 Infection

Clinical trial

WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks

Status: Completed, Estimated PCD: 2022-04-30